Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy ‐induced nausea and vomiting: A prospective cohort study
For patients with elevated substance P level, NK1 ‐RA (NK1 receptor antagonist, aprepitant) could be used, although these patients receive moderate emetic risk chemotherapy. This could improve the quality of life of patients receiving chemotherapy, and chemotherapy without dose reduction might have chance to improve treatment outcome for these pa tients. AbstractChemotherapy ‐induced nausea and vomiting (CINV) is an unbearable side effect. Identifying high emetic risk patients and providing more active antiemetics strategies are mandatory to improve the tolerability of chemotherapy. In this prospective cohort study, leptin, ghrelin, and substance P were measured at ba seline, day 3, and day 14 during the first cycle of chemotherapy. Nausea and vomiting were measured each day for the first 4 days of the first cycle of chemotherapy. Eighty‐two patients were enrolled. Colorectal cancer (61%) and gastric cancer (35.4%) were common cancer types. All patients receiv ed moderate emetic risk chemotherapy. Forty‐five (54.9%) patients had nausea, and 15 (18.3%) patients experienced vomiting. In univariate analysis, a higher level of baseline substance P, which is a target of NK1‐RA (Neurokinin 1 receptor antagonist), was a significant predictive marker for chem otherapy‐induced nausea [odds ratio (OR): 2.6, 95% confidence interval (CI): 1.02–6.62,p = 0.046]. Regarding chemotherapy‐induced vomiting, patients with higher levels of substance P had a greater chance of vo...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Hyung Soon Park,
Hye Sung Won,
Ho Jung An,
Sung Shim Cho,
Hyun Ho Kim,
Der Sheng Sun,
Yoon Ho Ko,
Byoung Yong Shim Tags: ORIGINAL RESEARCH Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Gastric (Stomach) Cancer | Gastroenterology | Neurology | Study